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A B S T R A C T
Background: Asthma is associated with accelerated rate of lung function (FEV1) decline.
Objective: To determine predictive factors associated with FEV1 decline in adult asthma.
Methods: A retrospective study was conducted in 229 asthmatics recruited from the University Asthma Clinic of
Liege. Subjects had at least two visits with post-bronchodilation (post-BD) FEV1 and minimum one year between
them. A multivariable linear regression analysis was conducted in order to come up with factors associated with
lung function decline.
Results: Post-BD FEV1 decline in % predicted. y−1 was 0.2 (95%CI -2.0 to 2.8) in the overall population. Our
population was made up of mild to moderate asthmatics [1] for 58%, aged 50 (41–60) years old, 62% were
female and 59% were atopic. Median ICS dose was 1000 μg beclomethasone equivalent (CFC)/day with 81%
treated at baseline. Time between visits was 46.8 ± 32.1 months. The univariate linear regression analysis
revealed a negative association between % predicted FEV1 decline and baseline ACQ (p < 0.0001) and blood
eosinophils (% and/mm3) (p < 0.0001 and p < 0.0001). A positive association was found between % pre-
dicted FEV1 decline and baseline pre-BD FEV1 (mL) values (p=0.001), blood neutrophils (%) (p=0.02),
change in blood eosinophils (%) (p < 0.0001), time between visits (months) (p < 0.0001). The predictive
variables for accelerated decline highlighted by the multivariable analysis (r2= 0.39) were change in blood
eosinophils (%) over time (p= 0.002) and time between visits (months) (p < 0.0001).
Conclusion: These findings highlight a new value for blood eosinophil counts as their increase over time predicts
greater lung function decline in asthma.
1. Introduction
Asthma is a chronic inflammatory airway disease associated with
reversible airway obstruction. Asthma patients are at risk of developing
structural changes (remodeling) resulting in persistent airflow limita-
tions [2–4]. On average, asthma patients have lower lung function than
healthy individuals [4] and their lung function (FEV1) decline can be
greater over time [3]. Nevertheless, not all asthma patients decline over
time, some show stable lung function and some others can outgrow
their asthma disease [5]. Previous studies have revealed risk factors for
accelerated FEV1 decline in asthma: low baseline lung function (FEV1%
predicted) [6,7], airway hyper-responsiveness [8], male gender [9],
cigarette smoking [10,11], late asthma onset [12], duration of disease
[4], frequent and severe exacerbations [13]. Moreover, the role of in-
flammation and eosinophilia in lung function decline has been high-
lighted with high eosinophil sputum numbers [5], high variability in
sputum eosinophils [14], as well as higher blood eosinophil numbers
[15] linked to accelerated rate of lung function decline in asthma.
Since, Newby et al. [14] found that eosinophilic airway inflammation
influences post-BD FEV1, especially when high variations over time
were observed, the purpose of this study was to evaluate potential risk
factors for accelerated lung function decline in a secondary care asthma
population, including evolution of blood and sputum eosinophils and
neutrophils over time.
2. Methods
2.1. Study design, setting and participants
A retrospective longitudinal study was conducted on adult (> 18-
year-old) asthmatics recruited from the University Asthma Clinic of
Liege, Belgium. Eligibility for this study was defined as patients who
https://doi.org/10.1016/j.rmed.2019.04.020
Received 4 February 2019; Received in revised form 5 April 2019; Accepted 29 April 2019
∗ Corresponding author. GIGA +4, CHU - B34, Quartier Hôpital, Avenue de l'Hôpital, 11, 4000 Liège, Belgium.
E-mail address: sgraff@uliege.be (S. Graff).
Respiratory Medicine 152 (2019) 60–66
Available online 30 April 2019
0954-6111/ © 2019 Elsevier Ltd. All rights reserved.
T
had at least two visits in stable state (exacerbation-free for the last
month) with post-BD FEV1 measurements and minimum one year be-
tween them. Two hundred and twenty-nine patients qualified for the
study in our database between February 2004 and January 2017.
Diagnosis of asthma was done by a Pulmonologist and based on the
presence of typical symptoms such as wheezing, breathlessness, chest
tightness, cough and at least one of the following: FEV1 increase of 12%
or more and 200mL following inhalation of 400 μg salbutamol or a
provocative concentration of methacholine causing a 20% fall in FEV1
of less than 16mgmL−1 [16].
First (V1) and last (Vx) visits of each patient were used to calculate
decline and evolution of blood and sputum eosinophil and neutrophil
counts and ICS dosage over time.
2.2. Variables
All variables used for the analysis were collected during patient
routine visits. All procedures were performed in the context of clinical
practice and the retrospective data collection was conducted with ap-
proval from the ethics committee of CHU Liège (2005/181).
2.3. Demographic data
Patient's age at visit, age at diagnosis (asthma onset), weight, and
tobacco status were routinely recorded. Quality of Life was assessed
using self-administered Asthma Quality of Life Questionnaire (AQLQ)
[17] and Asthma control by the Juniper Asthma Control Questionnaire
(ACQ) [18] and an Asthma Control Test (ACT) [19].
2.4. FENO measurement and spirometry
Patients underwent Fractional Exhaled Nitric Oxide (FENO) mea-
surements at flow rate of 50mL/s according to the ERS/ATS re-
commendations [20] (NIOX, Aerocrine, Sweden) followed by spiro-
metry with bronchodilation, and sputum induction on the same day.
2.5. Sputum induction and processing
Sputum induction and processing were performed as previously
described [21] using the whole expectorate.
Cell counts were estimated on samples centrifuged (Cytospin) and
stained with Hemacolor® Staining set after counting 500 non-squamous
cells (Merck chemical, Overijste, Belgium). Sputum cytology was ana-
lyzed and 4 phenotypes were defined: the eosinophilic phenotype with
≥3% sputum eosinophil count (and<76% neutrophil count), the
neutrophilic phenotype with ≥76% sputum neutrophil count (and<
3% eosinophil count), and the mixed granulocytic phenotype being a
combination of the above [22]. The paucigranulocytic phenotype was
defined as an inflammatory cell count below these thresholds.
2.6. Blood sampling
Serum total IgE were measured with the ImmunoCAP system
(Phadia AB, Uppsala; Sweden). A measure of Blood eosinophil and
neutrophil counts (% and/mm3) was also performed.
2.7. Treatment characteristics
Dosages of inhaled corticosteroids (ICS) and treatment with antil-
eukotrienes (LTRA), Long acting muscarinic antagonists (LAMA), Long
acting beta-2 agonists (LABA), Anti-IgE, anti-IL5 and oral corticoster-
oids (OCS) were recorded and used in the analysis. ICS doses were
classified as low (< 500 μg/d), moderate (> 500–1000 μg/d) or high
(> 1000 μg/d beclomethasone dipropionate – chlorofluorocarbon)
[23]. The evolution of ICS treatment between first and last visit was
also considered with change in ICS dose over time (delta) being ICS
dose at Vx minus ICS dose at V1.
2.8. FEV1 decline definition
Annual post-BD FEV1 changes obtained for each patient were ex-
pressed in % predicted.y−1 or mL.y−1. Post-BD FEV1 change was cal-
culated by subtracting the latest (Vx) measured value from the baseline
(V1) post-BD FEV1, subdivided by the number of months separating the
two measurements, and multiplied by 12. Post-BD FEV1, expressed as a
percentage of predicted values for age, sex and height using reference
equations from Quanjer GLI 2012 [24], was selected as our marker of
lung function for the linear regression model, as opposed to the abso-
lute value (in mL) which could simply reflect the physiologic effect of
aging or the influence of gender or height.
2.9. Statistical methods
Continuous variables were presented as mean and SD when nor-
mally distributed or as median and interquartile range when not nor-
mally distributed. Categorical variables were presented as frequencies
and percentages. A Kruskal Wallis analysis was used to compare post-
BD FEV1 decline among sputum inflammatory phenotypes and ICS ca-
tegories. T-test and Chi-2 were used to compare patients considered as
“decliners” (FEV1 decline> 0) and non-decliners (FEV1 decline ≤0).
FEV1 declines (in %pred) between patients with or without a step-up
treatment during follow-up were compared with a Mann-Whitney test.
Kaplan-Meier curves were generated to assess incidence of the lung
function decline. The cut-off of 150mL of lung function decline was
used.
The prediction of "decline in respiratory function per year" was
analyzed by conventional linear regression using independent variables
such as asthma onset, weight, tobacco status, and baseline (V1) mea-
surements of ACQ, FENO, pre-BD FEV1, reversibility, IgE, blood % eo-
sinophils and neutrophils, blood eosinophil counts (/mm3), sputum %
eosinophils and neutrophils, ICS doses, presence of antileukotrienes
treatment, time between visits, duration of disease and exacerbations.
Gender and height were not included in the analysis as FEV1% pre-
dicted is already adjusted for these values.
Changes from V1 to Vx (Deltas) for sputum and blood eosinophil and
neutrophil counts, and ICS dosage were also included in the univariate
analysis. Decline in lung function per year (in % predicted.y−1) was
used as the dependent variable.
After examining for all potential predictors, the univariate associa-
tion with the outcome, a stepwise backward linear regression was
conducted; initial model included variables with an association of
p < 0.20. Then, the best predictive model was conducted deleting
those variables that had the weakest association with the outcome
(p > 0.05). A p value < 0.05 was considered statistically significant.
Statistical analysis was done using STATA version 14.0 (Statistical
Software, College Station, TX: StataCorp LP).
3. Results
3.1. Patients’ characteristics at baseline
Two hundred and twenty-nine patients, seen between February
2004 and January 2017, had at least 2 visits with post-BD FEV1 mea-
surements, minimum one year apart.
Baseline demographic and clinical data of these patients are pre-
sented in Table 1.
Patients were mild to moderate asthmatics [1] for 58% of them and
42% severe asthmatics, aged 50 (41–60) years old, with 62% of female
and 59% of atopics.
Sputum induction was successful in 82% of the patients.
Eosinophilic inflammatory phenotype represented 52% of the popula-
tion, along with 14% neutrophilic, 5% mixed granulocytic and 29%
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paucigranulocytic phenotypes at baseline.
Most of these patients (81%) were treated with ICS at baseline with
a median dose of 1000 (400–2000) mcg beclomethasone equivalent
(CFC)/day. Nineteen percent of patients were not receiving treatment
at presentation, they had been sent to the asthma clinic by their
Table 1
Demographic and clinical data at first visit (baseline) and evolution over time
(deltas) for sputum and blood eosinophil and neutrophil counts.
N. 229
Gender (F) (%) 142 (62)
Age (years) 50 (41–61)
Age asthma onset (y) 35 (16–50)
Asthma onset category (%)
- Early (< 12) 46 (20)
- Intermediate (12–40) 73 (32)
- Late (> 40) 109 (48)
Time between First and last visit (months) 46.8 ± 32.1
Height (cm) 166.7 ± 8.8
Weight (Kg) 72.8 ± 15.9
BMI (kg/m2) 26.1 ± 5.2
Obesity (BMI> 30) (%) 51 (22)
Smoking status (%)Ex-smokersEx-smokers
Non-smokers 126 (55)
Current smokers 38 (17)
Ex-smokers 65 (28)
Atopy (Y) (%) (n= 220) 129 (59)
Pre FEV1 (mL) 2171 ± 768
Pre-BD FEV1 (% predicted) 74.2 ± 20.4
Post-BD FEV1 (% predicted) 81.9 ± 20.4
Post FEV1/FVC (%) 69.3 ± 14.6
Reversibility (%) 8.4 (3–17)
PC20M (mg/mL) (n=74) 2.12 (0.05–16.00)
FENO (ppb) (n=198) 28 (16–62)
Sputum eosinophils (%) (n= 187) 4.4 (0.7–32.0)
Sputum neutrophils (%) (n= 187) 44.2 (18.4–69.6)
Sputum inflammatory phenotypes: (%)
- Eosinophilic 97 (52)
- Neutrophilic 25 (13)
- Mixte 10 (5)
- Paucigranulocytic 55 (29)
Serum IgE. (kU/L) 165 (53–407)
Blood eosinophils (%) (n= 207) 3.2 (1.6–5.8)
Blood eosinophils (/μL) (n= 206) 188 (69–399)
Blood neutrophils (%) (n= 221) 55.7 (49.8–63.7)
Blood neutrophils (/μL) (n= 203) 4150 (1300–5170)
ACT score 13.1 ± 5.8
ACQ score 2.4 ± 1.3
AQLQ score 4.2 ± 1.6
ICS (Y) (%) 186 (81)
ICS dose 1000 (400–2000)
ICS category: (%)
- Steroid naïve 43 (19)
- Low dose 26 (11)
- Moderate dose 64 (28)
- High dose 96 (42)
OCS (Y) (%) 20 (9)
LTRA (Y) (%) 25 (11)
Decline mL.y−1 27.5 (−39.4–113.8) or 45.7
(± 210.6)
Decline FEV1. %pred.y−1 0.20 (−2.0-2.8) or 0.17 ± 7.8
Delta Sputum eosinophils (%) (n=135) −0.8 (−15.7–0.8)
Delta Sputum neutrophils (%) (n=134) 12.6 (−6.2 - 31.2)
Delta Blood eosinophils (%) (n=161) 0 (−1.4 - 0.9)
Delta Blood neutrophils (%) (n=138) 0.6 (−5.5 - 7)
Data are presented as mean ± SD or median and IQR. PC20M is presented as
geometric mean (min-max).
Low-dose ICS:< 500 μg/d; moderate-dose ICS:> 500–1000 μg/d; high-dose
ICS:> 1000 μg/d beclomethasone dipropionate – chlorofluorocarbon.
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life
Questionnaire; CRP, C reactive protein; FENO, fractional exhaled nitric oxide;
FEV1, forced expiratory volume in 1s; ICS, inhaled corticosteroid; LTRA,
Leucotriene Receptor Antagonist; PC20M, provocative concentration of me-
tacholine causing a 20% fall in FEV1; ppb, parts per billion; Delta, Vx value
minus V1 value.
Table 2
Comparison: “Declining” (FEV1 decline %pred> 0) sub-population (n=120)
to “not declining” (FEV1 decline %pred ≤0) sub-population (n= 109).
Demographic and clinical data at first visit (baseline).





Gender (F) (%) 74 (68) 68 (57) 0.081
Age (years) 51 (38–61) 51 (45–61) 0.6036
Age asthma onset (y) 32 (15–50) 41 (19–53) 0.1111
Disease duration 13 (1− 26) 8.5 (1− 22) 0.0671
Time between First and last
visit (months)
45.3 ± 33.4 48.2 ± 31.1 0.4970
Height (cm) 166.2 ± 8.8 167.2 ± 8.7 0.4082
Weight (Kg) 73.0 ± 15.8 72.7 ± 16.0 0.8926
BMI (kg/m2) 26.4 ± 5.6 25.9 ± 5.0 0.4654
Living area: (n= 167)
Countryside 30 (36.5) 54 (63.5) 0.001
Suburban 18 (21.9) 15 (17.6)
City 34 (41.6) 16 (18.8)
Smoking status (%)
Non-smokers 70 (64) 56 (47) 0.028
Current smokers 14 (13) 24 (20)
Ex-smokers 25 (23) 40 (33)
Atopy (Y) (%) 54 (50) 58 (48) 0.855
Pre-BD FEV1 (% predicted) 70.5 ± 20.2 74.2 ± 20.4 0.0076
Pre FEV1/FVC (%) 67.7 ± 10.8 69.0 ± 11.1 0.2727
Pre FEV1 (ml) 2037 ± 755 2171 ± 768 0.0115
Post-BD FEV1 (% predicted) 78.6 ± 19.9 81.9 ± 20.4 0.0193
Post FEV1/FVC (%) 68.9 ± 11.1 69.6 ± 11.6 0.6772
Post-BD FEV1 post (ml) 2282 ± 791 2479 ± 797 0.0615
Reversibility (%) 9.7 (3–20) 8 (3–14) 0.0382
PC20M (mg/ml) 2 .12 (0.05–16) 2.13 (0.05–16) 0.8477
FENO (ppb) (n= 198) 37.3 (18.5–73) 22.5 (14.4–49) 0.0056
Sputum eosinophils (%)
(n=187)
8.5 (0.8–43.6) 3.1 (0.7–17) 0.0044
Sputum neutrophils (%)
(n=187)
31.1 (14.9–64.2) 52.3 (28.7–73.3) 0.0052
Sputum inflammatory phenotypes: (%)
- Eosinophilic 54 (58) 43 (46) 0.301
- Neutrophilic 9 (10) 16 (17)
- Mixte 5 (5) 5 (5)
- Paucigranulocytic 25 (27) 30 (32)
Serum IgE. (kU/L) 178 (58–416) 138 (48–407) 0.5339
Blood eosinophils (%)
(n=207)
4.2 (2.1–7.8) 2.7 (1.3–4.3) 0.0011
Blood eosinophils (/μL)
(n=206)
262 (139–616) 126 (26–298) 0.0027
Blood neutrophils (%)
(n=221)








ACT score 12.8 ± 5.8 13.5 ± 5.9 0.5408
ACQ score 2.7 ± 1.4 2.1 ± 1.3 0.0032
AQLQ score 4.1 ± 1.6 4.3 ± 1.5 0.2339
ICS (Y) (%) 87 (80) 100 (83) 0.5000




- Steroid naïve 22 (20) 21 (18) 0.759
- Low dose 10 (9) 16 (13)
- Moderate dose 30 (28) 34 (28)
- High dose 47 (43) 49 (41)
OCS (Y) (%) 11 (10) 9 (8) 0.640
LTRA (Y) (%) 9 (8) 16 (13) 0.219
Data are presented as mean ± SD or median and IQR. PC20M is presented as
geometric mean (min-max).
Low-dose ICS:< 500 μg/d; moderate-dose ICS:> 500–1000 μg/d; high-dose
ICS:> 1000 μg/d beclomethasone dipropionate – chlorofluorocarbon.
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life
Questionnaire; CRP, C reactive protein; FENO, fractional exhaled nitric oxide;
FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LTRA,
Leucotriene Receptor Antagonist; PC20M, provocative concentration of me-
tacholine causing a 20% fall in FEV1; ppb, parts per billion.
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physicians in order to confirm asthma diagnosis and start the appro-
priate treatment based on their phenotype. Proportions of subjects in
low, moderate and high ICS treatment categories were 11%, 28%, and
42% respectively. Subjects receiving antileukotrienes, LAMA and LABA
treatments represented 11%, 11%, and 74% of the population respec-
tively. Mean (± SD) time between visits was 46,8 ± 32,1 months. Ten
percent of these patients were receiving chronic OCS while none were
receiving anti-IgE and antiI-L5 at baseline.
3.2. Lung function decline
In the overall population, the post-BD FEV1 decline was 0.2% pre-
dicted. y−1 (95%IC -2.0 to 2.8) or 27.5mL. y−1 (95%IC -39.4 to 113.8).
Fifty two percent of the population had slow (< 30mL. y−1), 11.8%
intermediate (30–60mL y−1), and 35.8% fast (> 60mL.Yr−1) post-BD
FEV1 decline, ranges previously defined by Sposato [25].
A hundred and nine patients (48%), however, did not decline (≤0%
predicted.y−1).
A sub-analysis comparing the clinical characteristics of patients
declining (decline % predicted.y−1> 0) and those not declining
(Table 2) was made. Smoking status was statistically different between
groups, with “decliners” having a larger proportion of smokers and ex-
smokers. Their lung function (pre-BD and post-BD FEV1) values were
higher at baseline. Reversibility and FENO values at baseline were
smaller in the declining group. Declining patients had also more neu-
trophils and less eosinophils in both compartments (airway and sys-
temic) than non-declining patients. Asthma control (ACQ) was sig-
nificantly better in the declining group.
Compared to baseline, a LAMA was added in 14 patients, a LABA in
43 patients, and a biologic treatment (14 Anti-IL5 and 4 Anti-IgE) in 18
patients. However, there is no significant difference in FEV1 decline (%
predicted.y−1) between patients with or without added treatment
during the follow-up (p=0.718).
Lung function decline was similar among inflammatory phenotypes
or ICS treatment categories. Moreover, when considering ICS treatment
change, there was no influence of stable, increased or decreased
treatment over time on post-BD FEV1 decline.
Kaplan-Meier survival curve is presented in Fig. 2. Sixty-seven
months are needed for half the patients to experience a loss of at least
150mL of their lung function. It is also apparent that no lung function
decline (of at least 150mL) can be seen before about 40 months (see
Fig. 3).
3.3. Factors associated with lung function decline
The univariate linear regression analysis (Table 3) revealed a ne-
gative association between % predicted post-BD FEV1 decline and
baseline ACQ (−1.2 (IC95% −1.9; −0.5), p < 0.001), exacerbations
(−1.1 (−2.2; −0.1), p= 0.039), and blood eosinophils (%) (−0.43
(−0.6; −0.2), p < 0.0001) or (/mm3) (−0.003 (−0.005; −0.001),
p < 0.0001). A positive association was observed between % predicted
post-BD FEV1 decline and baseline pre-BD FEV1 (mL) values (0.002
(0.000; 0.003), p= 0.001), blood neutrophils (%) (0.11 (0.01; 0.22),
p= 0.02), delta blood eosinophils (%) (0.42 (0.21; 0.63), p < 0.0001),
time between visits (months) (12.6 (10.4; 14.7), p < 0.0001).
The multivariable analysis (r2= 0.39) (Table 4) showed that vari-
ables in favor of post-BD FEV1 decline were an increase in blood %
eosinophils over time (0.29 (0.11; 0.46), p= 0.002) (Fig. 1) and longer
time between visits (months) (12.1 (9.3; 14.8), p < 0.0001) (Fig. 2).
No additional association was observed between post-BD FEV1 de-
cline and asthma onset, weight, tobacco status, total IgE levels, FENO
levels, reversibility (% predicted), ICS dose or antileukotrienes treat-
ment.
4. Discussion
In this retrospective study, we have shown that in a university
secondary care asthma clinic, patients with an increase in blood eosi-
nophil (%) counts over time or a longer follow-up duration are more at
risk of accelerated annual lung function decline than others.
A large proportion (42%) of patients were severe asthmatics, which
represents a proportion much higher than expected in the general po-
pulation (with 10% of severe asthmatics) [26]. These patients were
indeed uncontrolled despite high doses of ICS/LABA treatment. Most of
Table 3
Results of the linear regression - univariate analysis. N = 229*.




Coeff. IC 95% P value
Onset (years) 0.02 −0.02; 0.07 0.268
Weight (Kg) −0.02 −0.08; 0.04 0.516
Smoking status (%)
Non-smokers 0
Current smokers 2.4 −0.3; 5.3 0.091
Ex-smokers 1.7 −0.6; 4.0 0.153
ACQ −1.2 −1.9; −0.5 < 0.0001
FENO (ppb) −0.01 −0.03; 0.01 0.435
Pre-bronchodilator FEV1 (mL) 0.002 0.000; 0.003 0.001




Blood % Eosino −0.43 −0.6; −0.2 < 0.0001
Blood % neutro 0.11 0.01; 0.22 0.020
Delta Blood % Eosino 0.42 0.21; 0.63 < 0.0001
Delta Blood % Neutro −0.03 −0.15; 0.07 0.505
Blood Eosino/mm3 - 0.003 - 0.005; - 0.001 < 0.0001
Sputum % Eosino −0.04 −0.08; −0.0001 0.149
Sputum % Neutro 0.02 −0.01; 0.06 0.226
Delta Sputum % Eosino 0.04 −0.007; 0.08 0.099
Delta Sputum % Neutro 0.002 −0.03; 0.04 0.929
ICS dose −0.0005 −0.001; 0.0005 0.339
Delta ICS dose 0.0001 −0.0007; 0.0009 0.788
LTRA 2.0 −1.2; 5.2 0.230
Duration of disease −0.037 −0.099; 0.025 0.241
Exacerbations −1.148 −2.235; - 0.0617 0.039
Time between visits (months)
< 24 0 <0.001
≥24; < 36 5.6 3.2; 7.9
≥36; < 60 6.6 4.3; 8.9
≥60 12.6 10.4; 14.7
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life
Questionnaire; CRP, C reactive protein; FENO, fractional exhaled nitric oxide;
FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LTRA,
Leucotriene Receptor Antagonist; PC20M, provocative concentration of me-
tacholine causing a 20% fall in FEV1; ppb, parts per billion; Delta, Vx value
minus V1 value.
Table 4
Factors associated with lung function decline. Results of the linear regression –






Coeff. IC95% P value Coeff. IC95% P value
Delta blood %
eosino
0.42 0.21; 0.63 < 0.0001 0.29 0.11; 0.46 0.002
Time between visits (months)
< 24 0 <0.001 0 <0.001
≥24; < 36 5.6 3.2; 7.9 5.1 2.1; 8.0
≥36; < 60 6.6 4.3; 8.9 5.7 2.9; 8.5
≥60 12.6 10.4; 14.7 12.1 9.3; 14.8
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them also presented with an eosinophilic inflammatory phenotype
(52%) which is in line with what was previously reported [27,28].
These patients are indeed much in need of a frequent visit follow-up
and can be expected to decline faster than the general population of
asthmatics.
In previous studies, rates of post-BD FEV1 decline have varied from
38mL y−1 for asthmatics compared to 22mL y−1 in healthy subjects,
25.7 mL y−1 and 27.1 mL y−1 in severe asthma [14,29], 31.5mL y−1 in
asthmatic patients with frequent exacerbations vs 14.6 mL y−1 in those
with infrequent exacerbations [13], 28.4–39.7 mL y−1 in adult non-
smoker asthmatic patients in the Busselton cohort [11], to
16.1–21.5 mL y−1 in ICS treated asthmatic patients [30,31]. Decline in
our secondary care population, with 27.5 mL y−1, is consistent with the
observations reported in other populations.
Prognosis with regard to decline in lung function is worse for pa-
tients with eosinophilic blood counts increasing over time. Hancox [32]
recently showed that persistent blood eosinophilia was linked to ac-
celerated lung function decline in young adults with or without self-
reported asthma. They found that patients with a mean blood eosino-
philia> 0.4×109/L across four assessments had lung function decline
of a similar magnitude to ones observed among those who smoked 10
pack-years or more over the same time. Our observations go further and
show that an evolution towards an increase in blood eosinophils over
time in asthmatics predicts accelerated FEV1 decline. We found a linear
relationship between blood eosinophilia increasing over time and FEV1
decline.
Until now, several groups including ours have shown pretty con-
sistently that high blood eosinophils are associated with low FEV1
[33–36]. However, confirming the results of most previous longitudinal
studies, we show no association between blood eosinophils at baseline
and FEV1 decline [15,35,37–39]. This is therefore not surprising since it
has also been shown that high initial FEV1 are associated with greater
lung function decline, due most probably to a “regression toward the
mean” [40,41].
We are the first to show that a significant increase in systemic eo-
sinophilic inflammation, even in patients with normal baseline value,
can predict FEV1 decline while a unique measurement of blood eosi-
nophil counts fails to inform us on the likely evolution of the lung
function.
Perhaps surprisingly, the change in sputum eosinophils was not
associated with lung function decline. This may be explained by the fact
that it represents a phenotype shown to be responsive to increase ICS
both in controlled clinical studies and in real life [42,43]. Therefore,
sputum eosinophils are often associated with improvement in FEV1
when change in ICS dosing is appropriate.
Despite correction for annual decline, we also discovered that time
between visits had also a major impact on lung function decline. We can
observe a faster decline as time category increases with much higher
declines in the latest category (> 60 months period between first and
last visits). This could be related to the efficacy of ICS treatment over
time. Sin et al. [44] showed previously that ICS are mainly effective on
lung function over the first 3–4 months of treatment; after that period of
time, lung function decline seems to resume as observed in patients
receiving placebo. This being said, the compliance to treatment in this
study was not measured, which could have an impact on lung function
decline, especially for those having a long period of time between first
and last visit. It is also known that in healthy subjects, lung function
declines with ageing in a non-linear fashion; annual decline accelerates
with age, so as follow-up increases it can be expected that decline in-
creases [45,46].
Considering a cut-off of 30mL/year [5] for fast decline, we can
expect that it would take about 60 months to observe a 150mL decline
and this is confirmed by the KM curve. Indeed, on this curve we can see
that it takes about 67 months for 50% of our population to decline
significantly.
Many risk factors for accelerated lung function decline have already
been featured. Late onset of asthma, longer disease duration, frequent
asthma symptoms and severe exacerbations [47], airway hyperre-
sponsiveness (AHR), smoking, blood and sputum eosinophilia and
Fig. 1. Decline (% predicted.y−1) per Delta blood eosinophil counts (scatter
plot).
Fig. 2. Decline (% predicted.y−1) per time between visits. Categories: 0 < 24
months; 1≥ 24 and<36 months; 2≥ 36 and< 60 months and 3≥ 60
months.
Fig. 3. Kaplan-Meier survival curve of end point (lung function decline of
150mL).
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genetic predisposition could influence lung function decline in asthma
[48]. Also, FENO was found to be linked to accelerated declines in
asthma [49]. Late onset, highlighted as a risk factor for accelerated
decline by some authors, was not confirmed by our analysis. These
inconsistencies can be explained by the difference in late onset defini-
tion varying from 18 years old to an onset during the time of study
[9,12,50] or the possible misclassification of asthmatics in these studies
due to self-reported diagnostic [9,12].
Disease duration, usually associated with decline [51], was not
statistically associated with lung function decline in our model. In-
creased exacerbation rate at baseline was associated with lower lung
function decline in our population. A possible explanation being that
patients with high rate of exacerbation have a lower FEV1 to start with.
Indeed there is a significant negative correlation between FEV1 and
exacerbation rate at baseline in our population. Also, no information
regarding genetics was routinely collected in our database.
Neither could we confirm the results of Lange [3] or Ulrik [10]
showing that smoking is associated with greater lung function decline
which could be attributed to the small proportion (17%) of smokers in
our population, compared to more than 50% in theirs, leading to a lack
of significance. Coumou [49] showed that increased FENO levels were
associated with accelerated FEV1 decline, which was not confirmed by
our results. This could be explained by the differences in the population
studied with a population with less severe asthmatics, less atopic, and
with lower pack-year for Coumou as compared to ours, or the difference
in treatment regimens. Indeed FENO value has been shown to be greatly
influenced by atopy, smoking habit or ICS treatment [52].
This study presents some limitations. First, lung function decline
calculation was based on 2 measurements only. This is mainly due to
the retrospective nature of this study. Indeed, only visits with full
spirometry (post-BD FEV1) measurements and sputum collection were
considered for the study. All disease severities were present in our
population. Asthma, however, was diagnosed by specialists as opposed
to self-reported [11,12] and this population is representative of a uni-
versity secondary care population. We did not record adherence to
treatment. Time between first and last visits was also much variable but
decline was annualized to correct for that possible bias. Another lim-
itation of our study is its cross-sectional design with clinical and de-
mographic variable mostly considered at baseline with only a limited
number of parameters (sputum and blood cells, and time between
visits) being looked at longitudinally together with change in FEV1.
The usefulness of blood eosinophil counts has already been de-
monstrated as high blood eosinophils are associated with poor asthma
control and risk of exacerbations [36,53,54]. Moreover, blood eosino-
phils are able to predict the response to anti-IL5 and anti-IgE [55]
therapy [56]. Our findings highlight a new value for blood eosinophil
counts as their increase over time predicts greater lung function decline
in asthma. Moreover, it has a clinical implication as blood collection is
easily measured, more widely available, less time consuming and with a
higher success rate than sputum collection.
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